MedTrace Logo

Perfusion-Induced Hyperthermia for Metastatic Carcinoma

NCT02409108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-04-12

No results posted yet for this study

Summary

The purpose of this study is to gather information on how safe the hyperthermia treatment delivered via the Exatherm-TBH (the device that will heat your blood and deliver it back to you), added to the best supportive care is to patients who have advanced persistent or recurrent, unresectable Cancer.

Conditions

  • Metastatic Non-Small Cell Lung Carcinoma
  • Solid Tumor, Adult

Interventions

DEVICE

Exatherm-TBH system

One treatment of Total Body Hyperthermia

Sponsors & Collaborators

  • Exatherm, Inc

    collaborator INDUSTRY

  • Jonathan Kiev

    lead OTHER

Principal Investigators

  • Jonathan Kiev, MD · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-04-30
Completion
2019-02-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02409108 on ClinicalTrials.gov